Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence - PubMed (original) (raw)
Review
. 2014 Aug;109(8):1274-84.
doi: 10.1111/add.12557. Epub 2014 May 23.
Affiliations
- PMID: 24661324
- DOI: 10.1111/add.12557
Review
Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence
James C Garbutt et al. Addiction. 2014 Aug.
Abstract
Aim: The goal of this systematic review was to identify moderators of naltrexone efficacy in the treatment of alcohol dependence.
Methods: We searched Pubmed, CINHAL, Embase, PsycINFO and the Cochrane Library from 1990 to April 2012 and reference lists of pertinent review articles, which yielded 622 trial, pooled analysis and review articles. Using pre-established eligibility criteria, two reviewers independently determined whether abstracts contained evidence of demographic or biological characteristics, i.e. moderators, influencing naltrexone response in alcohol dependence. We assessed each publication for risk of bias and evaluated the strength of the body of evidence for each moderator.
Results: Twenty-eight publications (on 20 studies) met criteria for data synthesis. These included 26 publications from 12 randomized, placebo-controlled trials, three non-randomized, non-placebo studies and one randomized, non-placebo study. In addition, there were two publications from pooled analyses of four randomized, placebo-controlled trials. Family history of alcohol problems and the Asn40Asp polymorphism of the μ-opioid receptor gene showed a positive association with efficacy in four of five and three of five studies, respectively. Other moderators reported to be associated with efficacy included male sex (two of five studies), pre-treatment drinking (two of two studies) and high craving (two of five studies). However, the overall risk of bias in the published literature is high.
Conclusions: The identification of naltrexone-responsive alcohol-dependent patients is still in development. Studies to date point to two potential moderators-family history and presence of the OPRM1 Asn40Asp polymorphism-as having the strongest evidence. However, the data to date is still insufficient to recommend that any moderator be used in determining clinical treatment.
Keywords: Alcohol dependence; OPMR1 Asn40Asp polymorphism; craving; family history; moderators; naltrexone.
© 2014 Society for the Study of Addiction.
Similar articles
- Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis M. Oslin DW, et al. JAMA Psychiatry. 2015 May;72(5):430-7. doi: 10.1001/jamapsychiatry.2014.3053. JAMA Psychiatry. 2015. PMID: 25760804 Clinical Trial. - The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. Pettinati HM, et al. J Clin Psychopharmacol. 2006 Dec;26(6):610-25. doi: 10.1097/01.jcp.0000245566.52401.20. J Clin Psychopharmacol. 2006. PMID: 17110818 Review. - Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA, Hutchison KE. Ray LA, et al. Arch Gen Psychiatry. 2007 Sep;64(9):1069-77. doi: 10.1001/archpsyc.64.9.1069. Arch Gen Psychiatry. 2007. PMID: 17768272 Clinical Trial. - Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Palpacuer C, et al. PLoS Med. 2015 Dec 22;12(12):e1001924. doi: 10.1371/journal.pmed.1001924. eCollection 2015 Dec. PLoS Med. 2015. PMID: 26694529 Free PMC article. Review. - Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH; VA Cooperative Study #425 Study Group. Gelernter J, et al. Alcohol Clin Exp Res. 2007 Apr;31(4):555-63. doi: 10.1111/j.1530-0277.2007.00339.x. Alcohol Clin Exp Res. 2007. PMID: 17374034 Clinical Trial.
Cited by
- Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR, Mann K, Witkiewitz K. Roos CR, et al. Addict Biol. 2017 Nov;22(6):1528-1539. doi: 10.1111/adb.12427. Epub 2016 Aug 2. Addict Biol. 2017. PMID: 27480445 Free PMC article. Clinical Trial. - Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.
Biernacka JM, Coombes BJ, Batzler A, Ho AM, Geske JR, Frank J, Hodgkinson C, Skime M, Colby C, Zillich L, Pozsonyiova S, Ho MF, Kiefer F, Rietschel M, Weinshilboum R, O'Malley SS, Mann K, Anton R, Goldman D, Karpyak VM. Biernacka JM, et al. Neuropsychopharmacology. 2021 Nov;46(12):2132-2139. doi: 10.1038/s41386-021-01097-0. Epub 2021 Jul 23. Neuropsychopharmacology. 2021. PMID: 34302059 Free PMC article. - Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.
Worley MJ, Witkiewitz K, Brown SA, Kivlahan DR, Longabaugh R. Worley MJ, et al. Alcohol Clin Exp Res. 2015 Jan;39(1):93-100. doi: 10.1111/acer.12605. Alcohol Clin Exp Res. 2015. PMID: 25623409 Free PMC article. Clinical Trial. - Hazardous drinking and alcohol use disorders.
MacKillop J, Agabio R, Feldstein Ewing SW, Heilig M, Kelly JF, Leggio L, Lingford-Hughes A, Palmer AA, Parry CD, Ray L, Rehm J. MacKillop J, et al. Nat Rev Dis Primers. 2022 Dec 22;8(1):80. doi: 10.1038/s41572-022-00406-1. Nat Rev Dis Primers. 2022. PMID: 36550121 Free PMC article. Review. - A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?
Roberts W, Verplaetse TL, Ramchandani VA, McKee SA. Roberts W, et al. Alcohol Clin Exp Res. 2021 Jan;45(1):15-24. doi: 10.1111/acer.14514. Epub 2020 Dec 20. Alcohol Clin Exp Res. 2021. PMID: 33190310 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous